<DOC>
	<DOCNO>NCT01446016</DOCNO>
	<brief_summary>The major purpose research study well understand therapy work different patient . This study offer patient diagnosis advance metastatic breast cancer fail anthracycline base therapy . The investigator want see response breast cancer cell treat Chloroquine use combination chemotherapy . Chemotherapy anti-cancer drug give vein . The chemotherapy use study either Taxane ( Paclitaxel ) Taxane-like drug ( Abraxane , Ixabepilone Docetaxel ) .</brief_summary>
	<brief_title>Chloroquine With Taxane Chemotherapy Advanced Metastatic Breast Cancer Patients Who Have Failed Anthracycline ( CAT )</brief_title>
	<detailed_description>The purpose study determine anti-tumor activity combination Chloroquine combine Taxane Taxane-like chemo agent ( Paclitaxel , Docetaxel , Abraxane , Ixabepilone ) . The laboratory develop robust preclinical model utilize vitro system mammosphere ( MS ) culture vivo system human breast cancer xenograft allow investigator identify agent selectively target TICs , single agent combination . These model critical since tumor initiate cell ( TICs ) comprise small percentage tumor bulk , clinical tumor regression may observe inhibitor selectively target TIC self-renewal alone . Nonetheless , agent combination conventional therapy may effectively kill actively cycle fully differentiate cell TIC subpopulation , lead long term remission eradication cancer cell .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Chloroquine</mesh_term>
	<mesh_term>Chloroquine diphosphate</mesh_term>
	<criteria>1 . Females pathologically determine advanced metastatic breast cancer . 2 . Have progress treatment regimen include anthracycline . 3 . Have least 4 cycle anthracycline contain regimen 2 cycle progress treatment . 4 . Patients must measurable disease Response Evaluation Criteria Solid Tumors . 5 . ≥18 year age . 6 . ECOG PS 0 , 1 , 2 . 7 . Laboratory value within follow range : Hemoglobin ≥9.0gm/dL ( ≥1.5μmol/L ) ; transfusion permit . Absolute neutrophil count ≥1500/mm3 ( 1.5 x 109/L ) Platelet count ≥100,000/mm3 ( 100 x 109/L ) Creatinine ( Cr ) &lt; 2 X upper limit normal ( ULN ) , Cr clearance ( CrCl ) ≥30 Cockcroft Gault Alanine aminotransferase aspartate aminotransferase &lt; 2 X ULN ; liver metastases present must &lt; 5 X ULN , Bilirubin &lt; 2 X ULN , Potassium within normal limit , Magnesium within normal limit 8 . Negative serum pregnancy test time first dose woman childbearing potential ( WOCBP ) . For WOCBP , adequate contraception must use throughout study . For study , acceptable method contraception include reliable intrauterine device spermicide combination barrier method . Women already hormonal form birth control may continue treatment must also use barrier method . 9 . Ability understand requirement study , provide write informed consent authorization use disclosure protect health information , agree abide study restriction return required assessment . 10 . Patient must willing undergo breast biopsy require study protocol . 1 . Radiation therapy within 2 week ; chemotherapy noncytotoxic investigational agent within 4 week initiate study treatment . 2 . Evidence New York Heart Association class III great cardiac disease . 3 . History myocardial infarction , stroke , ventricular arrhythmia , symptomatic conduction abnormality within 12 month . 4 . History congenital QT prolongation . 5 . QT &gt; 500 . 6 . Concurrent severe uncontrolled medical disease ( i.e. , active systemic infection , diabetes , hypertension , coronary artery disease , congestive heart failure ) , opinion Investigator , would compromise safety patient compromise ability patient complete study . 7 . Symptomatic central nervous system metastasis . The patient must stable radiotherapy ≥2 week corticosteroid ≥1 week . 8 . Pregnant nursing woman . 9 . Hypersensitivity intolerance Chloroquine , Paclitaxel , Docetaxel , Abraxane , Ixabepilone Taxane like drug . 10 . Severe renal insufficiency ( CrCl &lt; 30mL/min [ Cockcroft Gault ] ) . 11 . History gastrointestinal bleeding , ulceration , perforation . 12 . Concurrent use potent CYP3A4 inhibitor , ketoconazole , itraconazole , clarithromycin , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconazole . 13 . Concurrent use potent CYP3A4 inducer , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentine , phenobarbitol , St. John 's wort .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Breast Tumors</keyword>
	<keyword>Cancer Breast</keyword>
	<keyword>Cancer Breast</keyword>
	<keyword>Human Mammary Carcinoma</keyword>
	<keyword>Mammary Carcinoma , Human</keyword>
	<keyword>Mammary Neoplasm , Human</keyword>
	<keyword>Mammary Neoplasms , Human</keyword>
	<keyword>Neoplasms , Breast</keyword>
	<keyword>Tumors , Breast</keyword>
	<keyword>Taxotere</keyword>
	<keyword>Chloroquine</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Taxol</keyword>
	<keyword>Ixabepilone</keyword>
	<keyword>Abraxane</keyword>
	<keyword>Metastatic Breast Cancer</keyword>
	<keyword>Advanced Breast Cancer</keyword>
	<keyword>Anthracycline</keyword>
</DOC>